http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
새로운 미백제인 천화분근, 하고초엽, 위령선근의 효능, 효과 및 안정화에 대한 연구
지홍근 ( Hong Guen Ji ),최정식 ( Jung Sik Choi ),이순근 ( Soon Keun Lee ),조용백 ( Yong Baik Cho ),표성수 ( Sung Soo Pyo ),한창균 ( Chang Kyun Han ),김주현 ( Joo Hyon Kim ),정기원 ( Ki Won Joung ),윤세준 ( Se Jun Yun ),신정주 ( Je 대한화장품학회 2004 대한화장품학회지 Vol.30 No.1
최근 기능성 화장품의 대두로 새로운 형태의 미백제들이 많이 출시되고 있다. 본 연구에서는 천화분근, 하고초엽, 위령선근을 이용하여 새로운 미백제를 개발하였다. 그러나 이러한 미백제는 용해성이 좋지 않고 빛, 열, 산소에 의하여 변색 및 함량의 변화를 가져온다. 먼저 천화분근, 하고초엽, 위령선근을 10배수의 50% 에탄올을 넣어 75∼85도에서 6∼8시간 추출한 후 여과, 농축, 건조하였다. 건조된 추출물을 이용하여 티로시나제 효소 활성 억제효과, 마우스의 색소세포를 이용한 B16 멜라닌 생성 억제 효과, brown guinea pig의 동물 피부의 미백효과 결과 다른 비교 샘플에 비하여 매우 우수한 결과가 나왔다. 또한 천화분근, 하고초엽, 위령선근을 안정화시키기 위해서 propylene glycol (PG)/hydrogenated lecithin/middle chain triglycerides (MCT)/glycerin/water를 고압균질화기를 이용하여 30∼50 nm인 리포좀을 만들었다. 이러한 리포좀은 기존의 처리되지 않은 추출물에 비하여 빛과 열에 3∼5배 안정성을 보였다. 이러한 실험을 위하여 particle size analyzer, freeze fracture transmission electron microscopy (FF-TEM), chromameter, HPLC의 분석장비를 사용하였다. Numerous novel ingredients have been introduced for the higher functionality of whitening cosmetics. Through the preliminary research, we have found Trichosanthes kirilowii root, Prunella vulgaris leaf and Clematis chinensis root have high whitening efficacy. But they are insoluble. Moreover the discoloration of and decrease in content take place when they are exposed to light, heat or oxygen. From Trichosanthes kirilowii root, Prunella vulgaris leaf and Clematis chinensis root, efficacious ingredients were ethanol-extracted by heating to 75∼85°C for 6∼8 h. These extracts have the inhibitory activity of tyrosinase and B16 melanin formation, thus enhancing whitening effect. We made liposomes using propylene glycol (PG)/hydrogenated lecithin/middle chain triglycerides (MCT)/glycerin/water and microfuidizer to stabilize extracts. The stability against heat and light was enhanced by 3∼5 times compared with untreated extracts. Particle size analyzer, freeze fracture transmission electron microscopy (FF-TEM), chromameter and HPLC are used for the analysis.
랫드에서 생약복합제 SKI306X 의 급성독성에 관한 연구
안재석(Jae Suk Ahn),김훈택(Hun Taek Kim),조용백(Yong Baik Cho),김환수(Hwan Su Kim),박광식(Kwang Sik Park),박병욱(Pyeong Uk Park) 한국응용약물학회 1996 Biomolecules & Therapeutics(구 응용약물학회지) Vol.4 No.1
SKI306X is a herbal extract prepared from three herbs Clematis mandshurica, Trichosanthes kirilowii and Prunella vulgaris. It showed strong antiinflammalory actions on carrageenan-induced edema, acetic acid-induced pain, adjuvant-induced arthritis, and oxygen radical-generated reactions. In this study, the acute toxicity of SKI306X was evaluated in rats by a single oral administration. Thirty male and thirty female rats were divided into 6 groups according to the dose levels, respectively. After oral administration of SKI306X with several doses (5.0 g/㎏, 3.3 g/㎏, 2.2 g/㎏, 1.5 g/㎏, 1.0 g/㎏), mortality, clinical signs, body weight, and gross findings in organs were examined. No toxic effect was shown in terms of mortality, clinical signs, body weight changes and gross findings. It is suggested the LD_(50) of SKI306X would be more than 5.0 g/㎏ in rats.
이민화(Min Hwa Lee),곽효성(Hyo Sung Kwak),송영준(Young Joon Song),조용백(Yong Baik Cho),신광범(Kwang Bum Shin) 한국약제학회 1986 Journal of Pharmaceutical Investigation Vol.16 No.4
The ingredients or particle size of active substance can significantly influence the release of the drug to the gastro-intestinal fluids and thereby affect the rate and extent of absorption. Rifampicin is administered with isoniazid or pyrazinamide as combined capsules from time to time to treat for tuberculosis effectively. The influence of isoniazid and pyrazinamide and particle size of rifampicin in rifampicin combined capsules was studied on the bioavailability of rifampicin. Single oral dose of 600㎎ rifampicin as capsules was administered to volunteers in fasting conditions and we studied the diffusion, and absorption rate constant and dissolution using Sartorius absorption and dissolution simulator. Isoniazid and pyrazinamide can affect on the bioavailability of rifampicin in rifampicin combined capsules and the absorption of rifampicin has no relationship with particle size of it. Also we can predict the bioavailability of rifampicin by using the Sartorius absorption and dissolution simulator.
생약복합제 SKI306X 의 랫드에 대한 4 주 경구 반복투여 독성연구
김훈택(Hun Taek Kim),안재석(Jae Suk Ahn),정인호(In Ho Jeong),김택수(Taek Soo Kim),류근호(Keun Ho Ryu),임광진(Guang Jin Im),조용백(Yong Baik Cho),김대기(Dae Kee Kim),김환수(Hwan Su Kim),박광식(Kwang Sik Park),김기협(Key H . Kim),박병욱(P 한국응용약물학회 1996 Biomolecules & Therapeutics(구 응용약물학회지) Vol.4 No.1
This study was performed to determine the subacute toxicities of SKI306X, an antiinflammatory herbal extract, in rats. SKI306X was administered orally to rats once a day for 4 weeks at doses of 0.3, 1.0, and 3.0 g/㎏/ day. Each group consisted of 20 male and 20 female rats, including 5 male and 5 female rats per group for an interim study at the end of 2-week administration and for a 2-week recovery study, respectively. Throughout the study, all rats survived and no adverse clinical signs were observed. Although male rats treated with high dose (3.0 g/㎏/day) of SKI306X showed slight loss of body weight (approximately 5%) in comparison with control animals during the administration period, their body weight loss was normally restored during the recovery period. No significant change was found in all hematological parameters of SKI306X-treated groups except for the decreased number of red blood cells in all female groups at the interim study. Statistically significant changes were observed in several blood enzyme levels of SKI306X-treated groups; however, most of these significant changes were within normal range and statistically significant values did not show dose-related responses. In SKI306X-treated groups, the absolute and relative weights of liver, heart, and stomach were statistically different from those of control group, but these differences disappeared at the end of recovery period and also drug-related gross and histopathological findings in these organs were not found. No other drug-related gross and histopathological findings were observed. It is concluded from the results of this study that non-toxic dose of SKI306X was estimated to be between 0.3 and 1.0 g/㎏/day and the maximum tolerated dose of SKI306X was assumed to be higher than 3.0 g/㎏/day.
항염작용을 갖는 신규 생약복합제 SKI306X의 분리 및 항염작용
박광식(Kwang Sik Park),김환수(Hwan Su Kim),안재석(Jea Suk Ahn),김택수(Taek Soo Kim),박병욱(Pyeong Uk Park),곽의종(Wie Jong Kwak),한창균(Chang Kyun Han),조용백(Yong Baik Cho),김기협(Key H. Kim) 대한약학회 1995 약학회지 Vol.39 No.4
Antiinflammatory activities of the solvent fractionates of several herbal medicines were investigated and SKI306X was prepared from the active principles of three herbal medicines, Prunella vulgaris, Trichosanthes kirilowii and Clematis mandshurica. SKI306X was shown to have strong inhibitory effects on acetic acid-induced pain, carrageenan-induced paw edema and adjuvant-induced arthritis. LD50 of SKI306X was more than 5g/kg in rat, so generally nontoxic. Chemical analysis revealed that oleanolic acid and rutin, which are known to have various antiinflammatory activities, were contained in it. These results suggest SKI306X may become a useful drug for the treatment of inflammatory diseases such as rheumatoid arthritis.
이민화,곽효성,송영준,조용백,신광범 한국약제학회 1989 Journal of Pharmaceutical Investigation Vol.19 No.2
The study was performed to compare the dissolution, diffusion and absorption characteristics using Sartorius dissolution and absorption simulator and in vivo bioavailability of commercially available rifampicin capsules. Both brands C and F showed similar dissolution patterns and absorption properties through artificial gastric barrier in Sartorius simulator. Diffusion rate constants through the membrane of brands C and F were 3.04×40^(-3) and 2.88×10^(-3)㎝/min, respectively. Rifampicin capsules were administered orally to six fasted healthy volunteers according to cross-over design. The pharmacokinetic parameters between brands C and F, maximum plasma drug concentration (C_(max)), the time to reach C_(max), absorption rate constant and area under the curve (AUC_(0-24hr)), elimination rate constant, and amount of drug excreted in urine were 6.11 and 7.27 ㎍/㎖, 2.71 and 1.52 hr, 0.6371 and 1.6456 hr^(-1), 57.84 and 57.28㎍·hr/㎖, 0.1891 and 0.1734 hr^(-1), 119.98 and 119.93 ㎎, respectively. On the basis of experimental results, it was concluded that the bioavailability of brand C rifampicin capsules was almost the same as that of brand F rifampicin capsules.